Y
Yingsheng Biology
A pioneer in technology development, quality control, and technical services in the field of clinical mass spectrometry in Chin
About Yingsheng Biology
Shandong Yingsheng Biotechnology Co., Ltd., operating as Yingsheng Biology, is a high-tech enterprise established in 2009 that integrates research and development, production, sales, and third-party medical testing services. The company was founded by Mr. Feng, who currently serves as the Chairman and Managing Director. He and his team are recognized for their deep understanding of the Chinese clinical mass spectrometry market.
Yingsheng Biology focuses on the in vitro diagnostics (IVD) market, particularly in the area of clinical mass spectrometry, which is considered a significant growth area in the diagnostics industry. The firm provides one-stop solutions for clinical mass spectrometry laboratories. Its business model encompasses the entire value chain from manufacturing analytical instruments and automated pre-processing platforms to producing a wide array of IVD reagents and offering medical testing services through its own inspection institutions in Hebei and Shandong. The company generates revenue through the sale of these products and services to hospitals and clinical laboratories.
The company's product portfolio is extensive, built around metabolomics and genomics to address birth defect screening, disease prevention, and human health services. Key products include the YS Ext 9900 and YS Ext 9050MD high-performance liquid chromatography-mass spectrometry (LC-MS) systems and the YS Ext 8600MD inductively coupled plasma mass spectrometer (ICP-MS). Yingsheng Biology also produces a range of diagnostic kits, such as those for neonatal genetic and metabolic disease screening, full-spectrum vitamin testing, and genetic testing for hereditary and drug-induced deafness. In 2020, the company developed a COVID-19 nucleic acid detection kit and received approval for its full-spectrum 14-vitamin testing kit.
Yingsheng Biology has achieved several key milestones, including securing multiple rounds of financing from prominent investors. The company completed a Series B financing round in November 2020 and a Series C round in March 2022, attracting capital from firms like CICC Capital, Far East Horizon, and Hillhouse. These funding rounds have been aimed at accelerating market expansion, consolidating the industrial chain, and maintaining a leading edge in product development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 23.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Medical Devices
- Sector
- Biotechnology, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES CEquity / VC | Mar 2022 | — | — | China Taiping Insurance · Far East Horizon · Sunz Fund · Hillhouse Capital | ↗ |
| SERIES B✓Equity / VC | Nov 2020 | $10M | $40M | Qianhai FOF · River Head Capital · Hillhouse Capital · CD Capital | — |
Growth signals
Latest recorded traffic for Yingsheng Biology is 1.9K monthly website visits, up 3700% over the last three months. Yingsheng Biology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yingsheng Biology in the Jinan ecosystem
The Yingsheng Biology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Hillhouse Capital
Qianhai FOF
River Head Capital
CD Capital- YCYuanBio Venture Capital
GL Ventures
Series B and later5 investors entered at this stage
Yuansheng BioVenture
Xiamen C&D
China Taiping Insurance
Far East Horizon- SFSunz Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yingsheng Biology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yingsheng Biology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








